商業快報

Biotech boss tells Europe to invest if it wants a homegrown sector
Argenx老闆:如果想建立歐洲本土產業就必須進行投資

Argenx is one of the bloc’s largest biotech companies but its shareholder base is dominated by US specialist investors
Argenx是歐盟最大的生物技術公司之一,但其股東主要是美國專業投資者。
Tim Van Hauwermeiren: ‘I think the last box . . .  [shareholders are] still waiting for will be the point of break-even, where we turn the corner on profitability’

Europe needs to learn from US shareholders willing to make big bets on biotech if it wants to create a thriving homegrown industry, according to the chief executive of Argenx, one of the bloc’s largest biotech companies. 

歐盟最大生物技術公司之一Argenx的執行長表示,如果歐洲想要創造一個蓬勃發展的本土產業,就需要向願意在生物技術領域大舉押注的美國股東學習。

您已閱讀9%(456字),剩餘91%(4746字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×